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ABSTRACT 
Background. Availability of large amount of clinical data 
is opening up new research avenues in a number of 
fields. An exciting field in this respect is healthcare, 
where secondary use of healthcare data is beginning to 
revolutionize healthcare. Except for availability of Big 
Data, both medical data from healthcare institutions 
(such as EMR data) and data generated from health and 
wellbeing devices (such as personal trackers), a 
significant contribution to this trend is also being made 
by recent advances on machine learning, specifically 
deep learning algorithms. 
Objectives. The objective of this work was to provide an 
overview of how automatic processing of Electronic 
Medical Records (EMR) data using Deep Learning 
techniques is contributing to understating of evolution of 
chronic diseases and prediction of risk of developing 
these diseases and associated complications. 
Methods. A review of the scientific literature was 
conducted using scientific databases Google Scholar, 
PubMed, IEEE, and ACM. Searches were focused on 
publications containing terms related to both Electronic 
Medical Records and Deep Learning and their synonyms. 
Results. The review has shown that a number of studies 
have reported results that provide unprecedented 
insights into chronic diseases through the use of deep 
learning methods to analyze EMR data. However, a major 
roadblock that may limit how effectively these 
paradigms can be utilized and adopted into clinical 
practice is in the interpretability of these models by 
medical professionals for whom many of them are 
designed.  
Conclusions. Despite the identified challenges automatic 
processing of EMR data with state-of-the-art machine 
learning approaches, such as deep learning, will push 
predictive power well beyond the current success rates. 
Hopefully, we will continue to see findings from these 
works to continue to transform clinical practices, leading 
to more cost effective and efficient hospital systems 
along with better patient outcomes and satisfaction. 
1 INTRODUCTION 
Health care systems across the world are adopting 
Electronic Medical Records (EMR), providing a collection 
of longitudinal data pertaining to patients’ health. Use of 
electronic records will significantly increase the 
availability of clinical data as well as impact on the 
potential of discovering of new disease patterns as well 
as providing personalized patient care by automatically 
processing of this vast quantity of data. Considering that 
richness of information contained in EMRs [1] and their 
potential to transform delivery of care [2], 
understanding the information contained in EMRs is 
becoming an important challenge. In this respect the rise 
of Deep Learning is accelerating automatic processing 
and understanding of EMR data. Especially the use of 
novel Deep Learning methods and architectures that can 
handle multi-dimensional, heterogenous and incomplete 
data are seen as particularly promising. These 
developments are foreseen to provide an increasing 
uptake in precision medicine through development of 
personalized health services enabled by analysis of 
individual and aggregated multimodal data residing into 
patients’ Electronic Medical Records (EMR). In this paper 
we provide a review of the combination of these 
technologies and their impact on the delivery of care. 
2 METHODS 
We conducted and reported the review according to the 
Preferred Reporting Items for Systematic Reviews and 
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Meta-Analysis (PRISMA) statement. Methods of the 
review process and eligibility criteria were established 
in and remained unchanged during the review. We have 
conducted a literature search using electronic databases 
Google Scholar, PubMed, IEEE, and ACM. The literature 
search was supplemented by manual retrieval of 
references contained in the articles. The literature search 
was conducted without time restrictions, using the 
following keywords: (EMR OR EHR OR PHR OR 
“Electronic Medical Records” OR “Electronic Health 
Records” OR “Personal Health Records”) and (“Deep 
Learning”). Majority of articles covered a period from 
2010 (beginning of the popularization of Deep Learning) 
up to 2017. Our search strategy retrieved 1790 articles. 
All identified titles and abstracts were screened for 
eligibility by 2 researchers (VO and LL). Articles were 
excluded based on two criteria: 1) They did not primarily 
focus on processing of health records using deep 
learning or 2) the work did not make use of Deep 
Learning methods. After this screening, there were 169 
full text articles that were further assessed for relevance. 
After this screening, there were 36 articles that were 
considered for this review. 
3 RESULTS 
Out of 1790 articles identified in the initial search, there 
were 36 articles that fulfilled eligibility criteria and were 
selected for review. We have divided the studies into two 
categories namely i) disease modelling using EMR data 
and ii) an overview of Deep Learning architectures and 
their use with EMR data. 
3.1 Building disease models 
Broadly, EMR are the collection of healthcare related 
data captured during a patient visit to a hospital or clinic, 
including disease diagnoses, medication prescriptions, 
procedures, surgeries, and lab test results among others. 
One of the most powerful applications of EMR data is for 
the refinement of personalized medicine strategies [3], 
as it provides an unparalleled amount of population-
sized, patient-level data that can be mined to directly 
inform clinical practice. In fact, Precision Medicine 
Initiative (https://www.whitehouse.gov/precision-
medicine) was launched with a $215 million investment 
to enable clinical practice to move from a “one-size-fits-
all approach” to more individualized care. When EMR 
data is combined with other modalities of data such as 
molecular features, biosensors, social determinants of 
health, and environmental exposures among others, a 
rich opportunity is created to study an individual 
patient’s disease in multiple dimensions and at multiple 
scales. Initiatives such as the personalized cancer 
therapy program [4] have utilized EMR resources to 
tailor treatment regimens to participating patients. 
Moreover, additional data parameters from EMR are 
used to augment current traditional Modified Early 
Warning Score (MEWS) algorithms, which “track-and-
“trigger” warnings of patient condition deterioration 
based on six cardinal vital signs [5], especially when 
combined with continuous monitoring of patients [6-10] 
Furthermore, discoveries from data-driven, EMR-based 
research can lead to actionable findings, such as 
identifying medication adverse reactions [11] [12] and 
predicting future disease risk [13]. In addition to 
enabling the provision of clinical care, EMR are also a 
powerful tool to assist fundamental research [14]. There 
are countless examples of research studies that 
discovered patterns of disease susceptibility [15, 16], 
comorbidity [17] [18], and trajectories [19, 20] using 
EMR. Linking EMR to other -omics data types within a 
network biology framework [21] has helped to elucidate 
contributions of various risk factors to disease etiology, 
including genetics [22] [23], environment [24], 
demography [25, 26], and combinations thereof [27]. 
Genetic and genomic data are often linked with clinical 
data via hospital-affiliated biobanks, which recruit 
individuals from the visiting patient population to obtain 
and “bank” their genetic data. This approach has led to 
the development of fields of research such as phenome-
wide association studies (PheWAS) [28], where a 
traditional genome-wide association study (GWAS) 
analysis is performed on a large retrospective hospital 
cohort allowing more freedom in phenotype selection. 
Recently, using whole-exome sequencing and a linked 
EMR system for over 50,000 participants, the DiscovEHR 
study revealed the clinical impact and phenotypic 
consequences of functional variants [29]. Adding in 
medication RNA expression signatures further facilitates 
pharmacological discoveries, ranging from drug 
discovery [30] and repurposing [31-33] to 
pharmacogenomics [34, 35]. In the next subsections, we 
provide two examples of disease modeling, namely 
diabetes and mental disorders. 
3.1.1 Using topological data analysis to characterize 
type 2 diabetes mellitus subgroups 
Type 2 diabetes mellitus (T2D) is highly complex, 
heterogeneous, and multifaceted disease that stems from 
an intricate interplay between genetic background and 
environmental factors [24]. While a diagnosis of T2D is 
diagnosed using a standardized assessment of blood 
glucose measures (e.g. hemoglobin A1c and/or fasting 
plasma glucose), it is clear that the etiological landscape 
of the disorder is mechanistically diverse [36]. Clinical 
presentation of the disease often varies and treatment is 
often hard for patients to manage [37] . For these reasons 
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and others, more personalized treatment styles need to 
be developed to facilitate better disease management. 
With this in mind, researchers developed an elaborate 
data-driven, unsupervised analysis coupling genetic and 
clinical data from EMR in order to better characterize the 
T2D disease landscape [38]. They utilized the Charles 
Bronfman Institute of Personalized Medicine’s BioMe 
biobank as a research cohort, which is a genotyped 
subset of patients from Mount Sinai Hospital with linked 
medical records (n=11,210). For all patients, they first 
only considered hospital encounters occurring within 30 
days of study enrollment, compiling all available 
laboratory test results, disease diagnoses (in the form of 
ICD-9 codes, but organized via Clinical Classifications 
Software [39], and medication prescriptions. 
To ensure high quality analysis, they used the robust T2D 
eMERGE electronic phenotyping algorithm [40, 41] 
(https://phekb.org/phenotype/); which details specific 
inclusion/exclusion criteria for multiple data types) to 
designate cases and controls for the study. This 
algorithm is open-source and can be obtained within the 
repository. Briefly, the groups are defined through 
multiple inclusion and exclusion criteria across multiple 
modes of information. For instance, individuals without 
T2D diagnosis, but who have an abnormal plasma 
glucose measurement are excluded from the control 
group. As much of the data is sparse, they only 
incorporated variables in which over half the patients 
had values for (n=73) in the actual analysis. 
Once the patient/control cohorts were designated, they 
performed topological data analysis (TDA)-based 
unsupervised clustering on the included clinical 
variables to identify any potential substructure of T2D 
using Ayasdi (http://ayasdi.com, Ayasdi Inc.). 
Additionally, for all data points, they calculated a cosine 
similarity metric to assess relatedness of clinical 
features. Next, they applied two filter functions, (1) L-
infinity centrality and (2) principal metric singular value 
decomposition to produce a patient-patient network. In 
this network, distance between nodes (i.e. distance 
between patients) reflects similarity of clinical feature 
composition. 
From the T2D topological network, they were able to 
identify three robust clusters of patients, which implicate 
potential subtypes of the disease. For the patients within 
each cluster, they compared genetic composition (i.e. 
SNP prevalence and pathway enrichment), disease 
comorbidities (via CCS classification), and clinical traits 
such as platelet counts. They discovered interesting 
genotype and phenotype disparities between clusters 
that begin to disentangle the extreme heterogeneity of 
the disease. For instance, patients in subtype 2 (~24% of 
all T2D cases) had the lowest weight, a unique genetic 
background (1,227 uniquely associated single nucleotide 
variants in 322 genes), and were enriched for cancer 
malignancy (e.g. cancer of bronchus and lung). These 
individuals may constitute the established cancer/T2D 
epidemiological connection [38] . This approach is an 
example of disease stratification. With these findings, 
they demonstrated that highly complex chronic diseases 
could be deconstructed using EMR and affiliated biobank 
data, which can both augment disease reclassification as 
well as precision medicine efficiency. 
3.1.2 Advancing mental illness prediction using deep 
learning 
Another compelling use of EMR-based research is the 
prediction of future disease outcomes in a data-driven 
approach using rich longitudinal patient data. Many 
chronic conditions are particularly difficult for the 
patient to manage and end up requiring large costs by 
healthcare systems due to continual re-hospitalizations. 
Mental illnesses, such as schizophrenia or attention 
deficit hyperactivity disorder (ADHD), are a 
heterogeneous group of conditions that are difficult to 
treat due to the interplay between psychological, 
psychiatric, and neurological aspects and inherent 
heterogeneity of symptoms, unique presentations, and 
somewhat imprecise and subjective diagnostic criteria. 
Additionally, socioeconomic and environmental factors 
[42], such as access to healthcare or social pressure, may 
prevent individuals from getting treatment or even 
knowing that they have a condition [43]. Therefore, 
continuous sensing of patients’ state in an unobtrusive 
manner [44, 45] such as through fitness trackers or 
smartphone sensors [46-48] provides valuable 
information in identifying early warning signs and serve 
as an aid in identifying most appropriate treatment 
plans.  
Recently, researchers developed a deep learning 
framework applied to a large-scale EMR database called 
Deep Patient [49] to construct predictive models for 
diseases across multiple domains, including mental 
illness. Using the EMR data, they collected all available 
clinical data (e.g. lab tests, etc.) for patients (n=704,587) 
with at least one disease diagnosis as well as five other 
recorded encounters up to 2014. They then further 
filtered clinical descriptors, removing those that 
appeared in >80% and <5% of patients. A random subset 
of these patients (n=200,000) was used as training data 
and a separate subset (n=81,284) was used for testing 
(n=76,284 for test, and n=5,000 for further feature 
validation). The model was trained using all data up to 
and including 2013, and performance was then assessed 
by actual outcomes manifesting in 2014. They used 
Stacked denoising autoencoders (SDAs), which map 
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features to hidden representations of the data at each of 
the three layers used, to learn general deep patient 
representations of all available features across all 
phenotypes. For all 78 assessed diseases, Deep Patient 
outperformed all other modeling strategies with a mean 
area under the ROC curve (AUC-ROC) of 0.773 (next 
highest was independent component analysis with 
0.695), emphasizing the utility of deep learning in 
chronic disease risk modeling. It is clear, however, that 
Deep Patient (along with other patient representation 
models) has more predictive power for certain diseases 
than others, which may result from inherent 
heterogeneity and other factors not contained within the 
EMR data. With Deep Patient for instance, prediction of 
diabetes mellitus with complications performed the best 
and disorders of lipid metabolism the worst with AUC-
ROCs of 0.907 and 0.561, respectively. Mental illness-
related diseases tended to have reasonable predictive 
power with all having AUC-ROCs over 0.6 and most (6/8) 
over 0.75. Attention-deficit and disruptive behavior 
disorders performed best and anxiety disorders worst 
with AUC-ROCs of 0.863 and 0.605 respectively.  
Deep Patient was able to quantify disease risk at the 
individual level, by assessing the proportion of the top 
one, three, and five predicted diseases per patient that 
appeared in different intervals within the test window 
(e.g. 30, 60, 90, and 120 days). Deep patient 
outperformed all other patient representation models in 
all aspects. As expected, predictions for the single top 
disease were more accurate than when considering the 
top three or five. Prediction accuracy was also positively 
correlated with time window length, with the most 
accurate predictions occurring for the 180-day window. 
3.2 Deep Learning architectures 
Automatic analysis of EMR data has been carried out 
using traditional machine learning methods. However, a 
number of issues, including characteristics of EMR data 
(such as heterogeneity, high-dimensionality, sparseness) 
have created scalability challenges, that is ability to 
automatically analyze large amount with low manual 
intervention (such as feature extraction for example). As 
such deep learning is particularly well positioned to 
analyze healthcare data, especially data contained in 
EMR. Deep learning is a method of machine learning that 
uses layers of models to predict outcomes. More 
specifically, it is a hierarchical neural network 
architecture that evaluates an input through a cascade of 
multiple layers. Each layer is composed of models, which 
compute upon data provided to it. The results of this 
computation, which are transformed versions of the 
original input, are then passed to another, higher-level 
model, continuing in this way until the top-level 
predictive model is reached, resulting in a composite 
model with abstracted combinations of features. Deep 
learning is increasingly being applied in the field of 
bioinformatics, such as drug discovery and, given a large 
enough training set, has outperformed other machine 
learning algorithms for predictive modeling of risk 
within EMR systems [40]. 
Traditional machine learning approaches have limited 
ability to process data in their raw form, requiring 
considerable expertise in designing feature extraction 
and selection. In contrast, deep learning methods learn 
the optimal features directly from the data, allowing 
automatic discovery of the representations required for 
classification. This is an especially important aspect 
when considering that EMR data is typically noisy, 
sparse, and incomplete as reported in [39]. In this 
respect, there have been several works that have used 
deep learning to analyze EMR data in order to better 
understand disease trajectories and predict risk. In 
terms of risk prediction Tran et. al [41] work was based 
on analysis of EMR data through restricted Boltzmann 
machines in order to provide suicide risk stratification. 
Work on DeepPatient used stacked autoencoders and 
logistic regression to predict a wide variety of disease 
diagnosis [39]. A number of other studies have used deep 
learning methods not only to predict the onset of 
diseases but also the likely timeframe of occurrence. In 
this respect Pham et. al’s DeepCare framework [42] 
creates two vectors on each patient admission, one for 
diagnosis and one for intervention whereby these 
vectors are concatenated and provided to an LSTM 
network able to predict the timeframe of the next 
intervention for diabetes and mental health. LSTMs were 
used also by Lipton et. al [43] specifically a two-layer 
LSTM with 128 memory cells each in order to predict the 
most likely diagnosis out of 128 possibilities. On the 
other hand Cheng et. al [44] trained a CNN on a temporal 
matrix with time on one dimension and clinical event on 
the other dimension for each patient in order to predict 
congestive heart failure and Chronic Obstructive 
Pulmonary Disease on 1127 and 477 cases for each 
disease respectively. Having experimented with a 
number of CNN techniques, they found that CNN with 
slow fusion provided the best predictive result. 
An alternative approach is presented by Choi et. al’s 
Doctor AI [45], where the objective was to model how 
physicians reach decisions by predicting future diseases, 
along with corresponding medication. Their trained GRU 
performed differential diagnosis with an accuracy 
comparable to physicians, achieving 79% recall. It 
should be noted that their system showed a similar 
performance using a different institution’s coding 
system, and also the performance on the publicly 
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available MIMIC dataset [46] increased by pre-training 
their models on their own private data, suggesting that 
the network has generalized well. In all of these tasks, 
whenever there was a comparison with conventional 
machine learning approaches, it was found that deep 
learning approaches resulted in better performance. 
4 CONCLUSION 
There are countless studies in addition to those 
described above that utilize EMR systems to reveal 
insights into chronic diseases and transform clinical 
practice. It is clear, however, that there are several 
roadblocks that limit how effectively these paradigms 
can be utilized and adopted into clinical practice. One 
substantial limitation, for instance, is in the 
interpretability of these models by medical professionals 
for whom many of them are designed. Several utilities 
have been developed to facilitate full comprehension of 
machine learning predictions. For example EHDViz [50] 
(http://ehdviz.dudleylab.org/), is a clinical dashboard 
that visualizes data streams, in real time, from an EMR. 
Outcomes from predictive models can be overlaid on 
visual flows such as these to put them in context of actual 
patient data. Despite these challenges, EMR-based 
research will continue to evolve to produce even more 
outstanding insights, especially through the use of deep 
learning. With nomenclature standardization practices 
improving and resources growing, integration with 
developing resources of other biological and 
environmental modalities (i.e. pollution data) and 
sensor-based data collection [51-53] will allow for a 
multi-scale understanding of findings. Clearly genetic 
data will play a crucial role in this process, however 
considering their scarce availability, we believe 
automatic processing of EMR data through Deep 
Learning methods is a viable candidate to contribute to 
better understanding of chronic diseases. Hopefully, we 
will continue to see findings from these works in 
transforming clinical practices, leading to more cost 
effective and efficient hospital systems along with better 
patient outcomes and satisfaction. 
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